belumosudil (Rezurock) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Breakthrough Therapy FDA Priority Review FDA
AACT PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1
  • InChIKey: GKHIVNAUVKXIIY-UHFFFAOYSA-N
  • Mol. Mass: 452.52
  • ALogP: 4.82
  • ChEMBL Molecules:
    belumosudil  
    belumosudil mesylate  
More Chemistry

Pharmacology

Alternative names

kd025

Organizations (12)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (21)

Approved Indications (1)


 

Graft vs Host Disease (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Autoimmune Diseases (Phase 1)

Biological Availability (Phase 1)

Bronchiolitis (Phase 2)

Bronchiolitis Obliterans (Phase 2)

Colorectal Neoplasms (Early Phase 1)

Drug Interactions (Phase 1)

Fibrosis (Phase 1)

Graft vs Host Disease (Phase 3)

Healthy Volunteers (Early Phase 1)

Idiopathic Pulmonary Fibrosis (Phase 2)

Immune System Diseases ()

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Lung Diseases (Phase 2)

Lung Transplantation (Phase 3)

Multiple Myeloma (Phase 1/Phase 2)

Neoplasms (Early Phase 1)

Psoriasis (Phase 2)

Renal Insufficiency, Chronic (Phase 1)

Scleroderma, Diffuse (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 28
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue